Agree Realty Corporation

13 hours ago · prnewswire.com

LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company will report full financial results for the third quarter of 2026 through a press release on Monday, November 9, 2026. The press release will be available in the News section of the Company's website, https://ir.adctherapeutics.com/news.

1 day ago · 247wallst.com

Long-term Treasury yields just pulled back sharply, and net-lease REITs stand to benefit more than almost any other corner of real estate.

2 days ago · seekingalpha.com

REITs have sold off despite many maintaining strong fundamentals. Some blue-chip REITs now offer unusually attractive valuations and yields. Accelerating rent growth and lower rates could drive significant upside.

3 days ago · 247wallst.com

Two monthly dividend REITs both raised guidance this year, but one is charging into data centers while the other is pulling back on deals to guard its balance sheet.

3 days ago · globenewswire.com

Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation

4 days ago · prnewswire.com

Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results Tanabe Pharma entered into exclusive sublicensing agreement with Nippon Shinyaku, bringing established Japanese oncology expertise and commercial capabilities to support potential introduction in Japan Supports anticipated regulatory and commercial milestones for ADC Therapeutics LAUSANNE, Switzerland, Oct. 29, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that its Japanese licensing partner, Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation), filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare on October 29, 2026, for ZYNLONTA® (loncastuximab tesirine-lpyl) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. In addition, Tanabe Pharma has entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd.

4 days ago · seekingalpha.com

The Undercovered Dozen highlights 12 lesser-covered stocks with actionable investment theses and recent catalysts. Featured companies include i-80 Gold, Hercules Capital, and Aya Gold & Silver, each rated Buy or Strong Buy for unique growth or yield drivers. Several stocks, such as Corning and AeroVironment, are rated Hold, with valuation and risk concerns tempering bullish sentiment despite recent price declines.

7 days ago · seekingalpha.com

Agree Realty offers a compelling entry point for long-term income investors at 14x AFFO and a near 5% yield. ADC's robust balance sheet, a credit rating of 'A,' and conservative payout ratio position it well amid higher rates and sector volatility. Despite lowered investment guidance, ADC's acquisition discipline, capital recycling, and record development activity support stable, long-term cash flows.

8 days ago · seekingalpha.com

U.S. markets remained unsettled as cracks emerged in the AI investment boom, while another oil-price surge complicated the inflation outlook ahead of Wednesday's Fed decision. Treasury yields fell for a third straight week as AI-related risk-off flows strengthened, with markets now assigning just 10% odds of an October hike despite still-elevated energy prices. REITs rallied for a third-straight week as earnings opened on an encouraging note: 15 REITs raised full-year FFO guidance, reinforcing the view that fundamentals remain healthier than recent price action.

8 days ago · globenewswire.com

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.